Published in Law and Health Weekly, May 24th, 2008
endometrial cancers; - Miltefosine (Impavido(R)): rights sold to Paladin Labs Inc. (TSX:PLB)
for approximately $8.9 million. Subsequent to First Quarter End - Cetrorelix: recruitment of 600...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.